| Title: |
1-Year Results From a Prospective Experience on CAS Using the CGuard Stent System: The IRONGUARD 2 Study |
| Authors: |
Sirignano P.; Stabile E.; Mansour W.; Capoccia L.; Faccenna F.; Intrieri F.; Ferri M.; Sacca S.; Sponza M.; Mortola P.; Ronchey S.; Praquin B.; Grillo P.; Chiappa R.; Losa S.; Setacci F.; Pirrelli S.; Taurino M.; Ruffino M. A.; Udini M.; Palombo D.; Ippoliti A.; Montelione N.; Setacci C.; de Donato G.; Ruggeri M.; Speziale F. |
| Contributors: |
Sirignano, P.; Stabile, E.; Mansour, W.; Capoccia, L.; Faccenna, F.; Intrieri, F.; Ferri, M.; Sacca, S.; Sponza, M.; Mortola, P.; Ronchey, S.; Praquin, B.; Grillo, P.; Chiappa, R.; Losa, S.; Setacci, F.; Pirrelli, S.; Taurino, M.; Ruffino, M. A.; Udini, M.; Palombo, D.; Ippoliti, A.; Montelione, N.; Setacci, C.; de Donato, G.; Ruggeri, M.; Speziale, F. |
| Publication Year: |
2021 |
| Collection: |
Università degli Studi di Siena: USiena air |
| Subject Terms: |
carotid artery disease; carotid artery stenting; stroke |
| Description: |
Objectives: The aim of this study was to evaluate the 1-year safety and efficacy of a dual-layered stent (DLS) for carotid artery stenting (CAS) in a multicenter registry. Background: DLS have been proved to be safe and efficient during short-term follow-up. Recent data have raised the concern that the benefit of CAS performed with using a DLS may be hampered by a higher restenosis rate at 1 year. Methods: From January 2017 to June 2019, a physician-initiated, prospective, multispecialty registry enrolled 733 consecutive patients undergoing CAS using the CGuard embolic prevention system at 20 centers. The primary endpoint was the occurrence of death and stroke at 1 year. Secondary endpoints were 1-year rates of transient ischemic attack, acute myocardial infarction, internal carotid artery (ICA) restenosis, in-stent thrombosis, and external carotid artery occlusion. Results: At 1 year, follow-up was available in 726 patients (99.04%). Beyond 30 days postprocedure, 1 minor stroke (0.13%), four transient ischemic attacks (0.55%), 2 fatal acute myocardial infarctions (0.27%), and 6 noncardiac deaths (1.10%) occurred. On duplex ultrasound examination, ICA restenosis was found in 6 patients (0.82%): 2 total occlusions and 4 in-stent restenoses. No predictors of target ICA restenosis and/or occlusion could be detected, and dual-antiplatelet therapy duration (90 days vs 30 days) was not found to be related to major adverse cardiovascular event or restenosis occurrence. Conclusions: This real-world registry suggests that DLS use in clinical practice is safe and associated with minimal occurrence of adverse neurologic events up to 12-month follow-up. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/34391704; info:eu-repo/semantics/altIdentifier/wos/WOS:000696806200015; volume:14; issue:17; firstpage:1917; lastpage:1923; numberofpages:7; journal:JACC: CARDIOVASCULAR INTERVENTIONS; https://hdl.handle.net/11365/1276054; https://www.sciencedirect.com/science/article/pii/S1936879821011365 |
| DOI: |
10.1016/j.jcin.2021.05.045 |
| Availability: |
https://hdl.handle.net/11365/1276054; https://doi.org/10.1016/j.jcin.2021.05.045; https://www.sciencedirect.com/science/article/pii/S1936879821011365 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.3681E382 |
| Database: |
BASE |